Hepatocellular carcinoma associated with liver-gender disruption in male mice.
Hepatocellular carcinoma (HCC) is a male-predominant cancer associated with chronic hepatitis. Like human viral hepatitis, murine Helicobacter hepaticus infection produces inflammation and HCC with a masculine bias. We used this model to identify potential mechanisms of male HCC predisposition. Male weanling A/JCr mice (n = 67) were gavaged with H. hepaticus or vehicle. At 1 year, mice were distributed into four groups: surgical castration, chemical castration, castration followed by dihydrotestosterone supplementation, or sexually intact controls. Responses to infection were compared with IFN-gamma challenge alone. At 21 months, there was no significant difference in hepatitis between groups. Neither castration nor androgen receptor agonism altered tumor incidence. Infected mice with severe, but not mild, disease exhibited a mosaic of alterations to sexually dimorphic genes and microsomal long-chain fatty acids. By microarray, tumorigenic hepatitis was strongly associated with liver-gender disruption, defined as the loss of a gender-identifying hepatic molecular signature. IFN-gamma alone produced similar changes, demonstrating a role for proinflammatory cytokines in this process. In conclusion, hepatocarcinogenesis in male mice with chronic hepatitis is maturationally imprinted and androgen-independent. Proinflammatory cytokines may promote HCC in a male-predominant fashion due to high sensitivity of the masculinized liver to loss of sex-specific transcriptional balance. Liver-gender disruption has pleiotropic implications for hepatic enzyme activity, lipid processing, nuclear receptor activation, apoptosis, and proliferation. We propose a multistep model linking chronic hepatitis to liver cancer through cytokine-mediated derangement of gender-specific cellular metabolism. This model introduces a novel mechanism of inflammation-associated carcinogenesis consistent with male-predominant HCC risk.
Rogers
Arlin B
AB
Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. abr@mit.edu
Theve
Elizabeth J
EJ
Feng
Yan
Y
Fry
Rebecca C
RC
Taghizadeh
Koli
K
Clapp
Kristen M
KM
Boussahmain
Chakib
C
Cormier
Kathleen S
KS
Fox
James G
JG
D000728:Androgens / Q000502:physiology; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018392:Genomic Imprinting; D016481:Helicobacter Infections / Q000503:physiopathology; D006505:Hepatitis / Q000382:microbiology / Q000473:pathology; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D020411:Oligonucleotide Array Sequence Analysis; D009919:Orchiectomy; D012334:RNA, Neoplasm / Q000235:genetics / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012727:Sex Characteristics
D000728:Androgens; D012334:RNA, Neoplasm